Trials / Completed
CompletedNCT00838396
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Indivior Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy and safety of arbaclofen placarbil (XP19986) compared to placebo in patients with gastroesophageal reflux disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XP19986 CR | |
| DRUG | Placebo for XP19986 CR |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2009-02-06
- Last updated
- 2016-09-14
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00838396. Inclusion in this directory is not an endorsement.